General methods. All solvents and reagents were purchased from commercial sources and used without further purification. The compounds were spotted on silica TLC plates (Merck, Si 60 , F254), visualized under UV-light at 254 nm or iodine over silica. Purification of the compounds for biological tests was performed on a Waters 2767 system equipped with a photodiode array and an ESI mass spectrometer using a XBridge Prep C18 (5 µm, 19 mm × 100 mm) column, equipped with an XBridge Prep C18 guard column (5 µm, 19 mm × 10 mm). The mobile phase consisted of water plus 0.1% formic acid (solvent A) and methanol plus 0.1% formic acid (solvent B), with an elution method of 0-1 min 5% B, 1-10 min 5%-95% B, 10-12 min 95%, 12-13 min 95%-5% B, 13-18 min 5% at a flow rate of 20 mL/min.
suspended in a mixture of ethanol (4 mL) and benzene (2 mL). Sulfuric acid (300 μL) was added and the reaction mixture was heated at reflux with azeotropic removal of water via Dean-Stark trap. After the reaction was complete, the organics were removed in vacuo. (459 μL, 2.38 mmol) was added dropwise at room temperature. The resulting mixture was stirred at room temperature for 4 hours, and then concentrated in vacuo. The residue was redissolved in a mixture of 4N NaOH (1.2 mL) and MeOH (5 mL) and the mixture was allowed to heat at 50 ºC for another 2 hours. After the reaction was complete, the mixture was partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous layer was then treated with 6N HCl to pH 3 and the free carboxylic acid was extracted into ethyl acetate (2 x 15 mL). After drying over MgSO 4 
2-(1-(t-butoxycarbonyl)piperidin-4-yloxy)nicotinic acid (7b). To a stirred

OH
solution of 25a (139 mg, 1 mmol) in MeOH (3 mL), methylhydrazine (54 μL, 1.05 mmol) was added. The mixture was stirred at 65 ºC for 4 hours, followed by the addition 50% hydroxylamine (50% wt in H 2 O, 324 μL, 4 mmol). The resulting mixture was kept at 65ºC for another 6 hours. After the reaction went to completion, the solution was concentrated to afford the title compound as an orange solid (173 mg, yield: 95%) without further purification.
LC-MS purity: 98%. of quinoline-5-carbaldehyde (683 mg, 4.35 mmol) in MeOH (5 mL) at 0 ºC and stirred for 8 hours at room temperature. The reaction was quenched by ice pieces and concentrated under reduced pressure. The residue was suspended in water (30 mL) and extracted into ethyl acetate (2 x 30 mL). The combined organic layers were washed with brine, dried over MgSO 4 and concentrated under vacuum. The resulting residue was re-dissolved in a solution of Et 3 N (1.21 mL, 8.70 mmol) and DCM (5 mL), followed by the addition of methanesulfonyl chloride (355 μL, 4.57 mmol) at 0 ºC. After the reaction was complete, the reaction was quenched by ice pieces and concentrated under reduced pressure. The residue was suspended in water (30 mL) and extracted into ethyl acetate (2 x 30 mL). The combined organic layers were washed with brine, dried over MgSO 4 and concentrated under vacuum. The above residue was dissolved in DMSO (4 mL) and NaCN (256 mg, 5.22 mmol) was added. The mixture was stirred at 60 ºC for 1 hr. EtOAc (50 mL) was added to the reaction mixture, and the organic layer was washed successively with water (50 mL) and brine (50 mL), and dried over MgSO 4 . The resulting residue was purified by column chromatography over silica gel to afford the title compound as an off-white solid (157 mg, yield: 22%). LC-MS purity: 97%. 5-(4-fluoro-2-(piperidin-4-yloxy)phenyl)-1,2,4 5-(2-fluoro-6-(piperidin-4-yloxy)phenyl)-1,2,4 
2-(quinolin-5-yl)acetonitrile (30a
3-benzyl-
3-benzyl-5-(5-fluoro-2-(piperidin-4-yloxy)phenyl)-1,2,4-oxadiazole
3-benzyl-5-(5-chloro-2-(piperidin-4-yloxy)phenyl)-1,2,4-oxadiazole
3-benzyl-
3-benzyl-5-(3-(piperidin-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole (17)
N
3-(3-methoxybenzyl)-5-(2-(piperidin-4-yloxy)phenyl)-1,2,4-
3-(3-methoxybenzyl)-5-(2-(piperidin-4-yloxy)pyridin-3-yl)-
1,2,4-oxadiazole (19)
General oxadiazole formation was followed to give the title compound as yellow oil in 43% 
5-(4-methoxy-2-(piperidin-4-yloxy)phenyl)-3-(3-methoxybenzyl)-
5-(4-fluoro-2-(piperidin-4-yloxy)phenyl)-3-(3-methoxybenzyl)-
1,2,4-oxadiazole (21)
General oxadiazole formation was followed to give the title compound as a yellow solid in 44% General reductive-amination was followed to give the title compound as light yellow oil in 68% 
5-(4-chloro-2-(piperidin-4-yloxy)phenyl)-3-(3-methoxybenzyl)-
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Enzyme inhibition assay. All IC 50 determinations were carried out using a 7-diethylamine-3-(4'maleimidylphenyl)-4-methylcoumarin (CPM) fluorescence assay, as described previously for PvNMT [1] and HsNMT1. [2] IC 50 of an inhibitor was calculated by a nonlinear regression analysis using GraFit 7.0.1 version (Erithacus Software Limited, UK).
The values are the mean value of two determinations; standard deviation is within 20% of the IC 50 unless otherwise specified. K m values of peptide substrates were determined as described previously: [2] 3.64 µM for All assays were carried out in triplicate.
Crystallography. Crystals of the ternary complex of the non-hydrolysable co-factor and compound bound to PvNMT were obtained as described previously. [4] X-ray diffraction data were collected on synchrotron beamlines at Diamond Light Source, Harwell, UK, and processed using XDS and SCALA implemented within xia2.
Structure refinement was by maximum likelihood methods implemented in REFMAC5 using the protein chains of 4A95.pdb [5] as a starting model, interspersed with cycles of model building and adjustment using COOT. A summary of data collection and refinement statistics is in Supporting Information.
The coordinates and structure factor files have been deposited in the Protein Data Bank under the accession codes 4UFV (PvNMT-NHM-18), 4UFW (PvNMT-NHM-22) and 4UFX
(PvNMT-NHM-19). Table S1 . Investigation of optimal side chain position and linkage group R free is the R cryst calculated with 5% of the reflections omitted from refinement.
SUPPLEMENTARY TABLES
d Root-mean-square deviation of bond lengths or bond angles from ideal geometry.
